Bortezomib 3.5 mg Injection — Targeted Proteasome Inhibitor for Multiple Myeloma & Lymphoma Bortezomib 3.5 mg Injection contains bortezomib, a targeted proteasome inhibitor chemotherapy medicine indicated for the treatment of multiple myeloma and mantle cell lymphoma in adults. By blocking key protein‑processing units inside cancer cells, bortezomib triggers stress and cell death, slowing tumour growth and improving response to therapy. It is administered as an intravenous (IV) or subcutaneous (SC) injection by trained oncology clinicians under strict medical supervision. Due to risks such as bone marrow suppression, neuropathy, and organ function changes, regular blood tests and clinical monitoring are required throughout treatment.